This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Specker, C. Articles by Schneider, M. Search for Related Content PubMed Articles by Specker, C. Articles by Schneider, M. Social Bookmarking                   What's this?

Cerebral microemboli in patients with antiphospholipid syndrome

Department of Rheumatology, Heinrich-Heine-University

J. Rademacher

Department of Neurology, Heinrich-Heine-University

D. Söhngen

Department of Hematology, Heinrich-Heine-University

M. Sitzer

Department of Neurology, Heinrich-Heine-University

I. Janda

Department of Cardiology, Heinrich-Heine-University, Moorenstr. 5, D-40225 Düsseldorf, Germany

M. Siebler

Department of Neurology, Heinrich-Heine-University

H. Steinmetz

Department of Neurology, Heinrich-Heine-University

M. Schneider

Department of Rheumatology, Heinrich-Heine-University

CNS involvement is one of the hallmarks underlying poor prognosis in SLE and for therapeutic strategies it is difficult to assess which patients are at risk. As detectability of cerebral microembolic signals (MES) using long-term transcranial Doppler ultrasonography (TCD) proved to be predictive of past and future thromboembolic events in patients with carotid artery stenosis, we investigated whether MES might be similarly useful in patients with antiphospholipid syndrome (APS).

Our study population consisted of 46 SLE patients and five with primary APS (pAPS). Twelve of the 46 patients with SLE, 10 of them with secondary APS (sAPS), and four of five patients with pAPS had a history of cerebrovascular ischaemia (CVI). MES in the middle cerebral artery were detected in 14 of 16 patients with and in one of 35 without CVI (P < 0.001). Antiphospholipid antibodies (aPL) were positive in 12 of 15 patients with and 18 of 36 without MES, and the rate of MES correlated to the titre of aPL. MES from APS patients resembled in their energy distribution those from patients with symptomatic carotid disease and were significantly different from those associated with artificial heart valves.

In conclusion, cerebral MES are detectable in APS patients and correlate with a history of CVI. Whether this innovative method may provide individual risk assessment in APS patients has to be addressed in prospective studies.

Key Words: antiphospholipid syndrome • SLE • microemboli • cerebrovascular ischaemia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A Katzav, J Chapman, and Y Shoenfeld CNS dysfunction in the antiphospholipid syndrome Lupus, December 1, 2003; 12(12): 903 - 907. [Abstract] [PDF]

				R L Brey, J Chapman, S R Levine, G Ruiz-Irastorza, R H. Derksen, M Khamashta, and Y Shoenfeld Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 Lupus, July 1, 2003; 12(7): 508 - 513. [Abstract] [PDF]

				J. CHAPMAN and Y. SHOENFELD Neurological and Neuroendocrine-Cytokine Inter-relationship in the Antiphospholipid Syndrome Ann. N.Y. Acad. Sci., June 1, 2002; 966(1): 415 - 424. [Abstract] [Full Text] [PDF]